VentriNova is revolutionizing cardiac regenerative medicine by reversing cardiac damage pharmacologically. VentriNova’s pioneering approach of cyclin A2 modulation stimulates endogenous growth of new myocytes (heart muscle cells).
(Photo credit: Cover of Circulation Research 6/22/07)
Delivery of VN100 via cardiac catheter into the infarcted heart where viral particles diffuse rapidly in myocardial tissue and stimulate the division of mature healthy cardiomyocytes in the infarct border zone and expand the pool of committed cardiac progenitor cells in order to repopulate the infarct zone and restore cardiac contractile function.
NEWS AND EVENTS
VentriNova has been selected as one of 50 innovative healthcare companies in a global competition to be highlighted as part of the HIVE at TEDMED 2013 and VentriNova’s founder Dr. Hina W. Chaudhry has been named a TEDMED Innovation Scholar.